Antimicrobials
DAPTOmycin

DAPTOmycin

Restricted

Low
N/A

Spectrum of Activity

Dosing

General Information

Targeted therapy of resistant gram positive infections with:

  • MRSA or other Gram-positive infections in patients who cannot receive 1st line agents
  • Vancomycin Resistant Enterococcus

Note:

  • DO NOT use for pneumonia, inactivated by pulmonary surfactant

Creatine kinase at baseline and weekly during prolonged therapy. Consider holding statins while on therapy

  • Myopathy, including rhabdomyolysis
  • GI side effects common
  • Rash
  • Phlebitis
  • Increased INR
  • Rare eosinophilic pneumonia

Statins and fibrates - Increased myopathy. Monitor creatine kinase or hold while on daptomycin therapy.

  • Can obtain sensitivities on request
  • Higher doses used for endovascular infection.
  • Recommend Infectious Disease Consultation
  • Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

Urine penetration: Therapeutic

Lung penetration: Poor

CSF penetration: Poor